Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMIST: Infliximab Optimization in Crohn's Disease
NCT00752622Phase 4Terminated
- Sponsor
- Merck & Co.
- Start
- Nov 2008
- Primary completion
- Jun 2010
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 4 trial of infliximab in Crohn's disease, sponsored by Merck & Co.. Started Nov 2008; status: terminated.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00752622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00752622.